Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 18/20 | 0.59 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | ESRRB | O95718 | 2/20 | 0.40 |
| ▸ | ESRRA | P11474 | 2/20 | 0.40 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924370 | 0.85 | ESR1 (0.67) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL3922723 | 0.81 | ESR1 (0.63) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL3937893 | 0.79 | ESR1 (0.59) | ESR1ESR2 | |
| SCHEMBL13960114 | 0.79 | ESR2 (0.66) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL3933875 | 0.75 | ESR1 (1.00) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL3922463 | 0.74 | ESR1 (0.63) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL3935566 | 0.74 | ESR1 (1.00) | ESR1ESR2TNIKESRRBESRRA | |
| SCHEMBL13958288 | 0.70 | ESR1 (0.46) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL13607751 | 0.69 | ESR1 (0.56) | ESR1ESR2 | |
| SCHEMBL27659339 | 0.69 | ESR1 (0.50) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | disclosed |